NEW ORLEANS--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today highlights new data on real-world experience utilizing the antegrade approach via nephrostomy tube for administration of JELMYTO (mitomycin) for pyelocalyceal solution. This data adds to a growing body of evidence on the safety and efficacy profile of the antegrade method of administration for JELMYTO. These data were presented during a podium presentation at the 2022 American Urological Association (AUA) annual meeting in New Orleans, Louisiana.
JELMYTO is efficacious as a chemoablative agent in adult patients with low grade upper tract urothelial cancer, and while its FDA approved for both antegrade and retrograde administration, prior reports are limited to the retrograde experience, said Kyle Rose, MD, Urologic Oncology Fellow at Moffitt Cancer Center in Tampa, Fla., and study investigator. These data provide additional evidence that instillation via a nephrostomy tube is an effective instillation method with a safety profile that offers an encouraging option to appropriate patients.
Dr. Rose presented the abstract Antegrade Administration of Reverse Thermal Mytomycin Gel for Primary Chemoablation of Upper Tract Carcinoma via Percutaneous Nephrostomy Tube: A Multi-Institutional Real-World Experience (Abstract PD58-06) during a podium presentation at the AUA annual meeting on Monday, May 16.
All 71 patients in the Phase 3 OLYMPUS trial utilized the retrograde approach to administer JELMYTO, therefore we are pleased to see real-world evidence that supports the utilization of the antegrade approach giving physicians and patients more options to administer JELMYTO based on their preference and experience, said Mark Schoenberg, MD, Chief Medical Officer, UroGen.
About This Study
The real-world data from this retrospective analysis was pooled from Moffitt Cancer Center, Tampa, FL; University of Missouri School of Medicine, Columbia, MO; The University of Texas MD Anderson Cancer Center, Houston, TX; and Mayo Clinic, Rochester, MN.
Twenty-six patients received nephrostomy tube administration of JELMYTO, six patients (23%) had solitary kidneys. Nine patients (35%) went on to receive at least one dose of maintenance therapy. Ureteral stenosis occurred in four patients (15%). Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and hematuria (8%). No patients had impaired renal function during follow-up and no deaths occurred.
Thirteen patients (50%) exhibited a complete response at post-induction ureteroscopy while 12 patients (46%) had a partial response. One patient experienced progression to invasive disease and required a nephroureterectomy. At a median follow-up of seven months (IQR 3-9) post-induction, no patients who experienced a complete response recurred.
The limitations of this study include the retrospective nature, small sample size, and pooled reporting of results. There is a need for larger studies with longer follow-up to study more conclusively any potential advantages of antegrade JELMYTO administration when compared to retrograde instillation.
About the Pivotal OLYMPUS Study
OLYMPUS (Optimized DeLiverY of Mitomycin for Primary UTUC Study) was an open-label, single-arm Phase 3 clinical study of UGN-101 JELMYTO (mitomycin) for pyelocalyceal solution, to evaluate the safety, tolerability and tumor ablative effect of JELMYTO in patients with low-grade Upper Tract Urothelial Cancer UTUC (LG UTUC). Seventy-one patients were treated at clinical sites across the United States and Israel. Study participants were treated with six weekly instillations of JELMYTO administered via a standard catheter. Four to six weeks following the last instillation, patients underwent a Primary Disease Evaluation (PDE) to determine Complete Response (CR), the primary endpoint of the study. PDE involved a ureteroscopy and wash cytology, a standard microscopic test of cells obtained from the urine to detect cancer and for cause biopsy. Patients who achieved a CR at the PDE timepoint were eligible for the maintenance phase of the trial, during which they could receive monthly maintenance instillations for up to 12 months and were assessed to determine the durability of response with JELMYTO.
In the OLYMPUS study, data was generated for the retrograde administration of JELMYTO. In that study population ureteric obstruction was reported in 58% (n=41) of patients receiving JELMYTO, including 17% (n=12) of patients who experienced Grade 3 obstruction.
About LG UTUC
LG UTUC is a rare disease managed by endoscopic methods and radical nephroureterectomy. Endoscopic resection and laser ablation attempt to preserve the kidney, though there is a high risk of recurrence that may eventually necessitate removal of the kidney. Although kidney removal is the gold standard for treatment of high-grade UTUC, it may be over-treatment in LG UTUC, as kidney removal offers similar five-year survival as kidney-sparing procedures but is associated with significant morbidity. JELMYTO is efficacious as a primary chemoablative therapy in patients with LG UTUC.
About JELMYTO
JELMYTO (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel indicated for primary chemoablative treatment of LG UTUC in adults. It is recommended for primary treatment of biopsy-proven LG UTUC in patients deemed appropriate candidates for renal-sparing therapy. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow.
APPROVED USE FOR JELMYTO
JELMYTO is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).
IMPORTANT SAFETY INFORMATION
You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:
Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose.
Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.
How will I receive JELMYTO?
After receiving JELMYTO:
JELMYTO may cause serious side effects, including:
The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.
You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration. Visit http://www.fda.gov/medwatch or call 1800FDA1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.
Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options.
UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGens sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGens first commercial product Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit http://www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding whether future studies could demonstrate any potential advantages of antegrade administration of JELMYTO as compared to retrograde instillation; optimism regarding the effectiveness of the antegrade approach; RTGels potential to improve the therapeutic profiles of existing drugs; and UroGens sustained release technology making local delivery potentially more effective as compared to other treatment options. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: results from initial reports of the antegrade administration of JELMYTO may not be indicative of results that may be observed in the future; potential safety and other complications from the antegrade administration of JELMYTO; the timing and success of clinical trials and potential safety and other complications thereof; the ability to obtain and maintain regulatory approval; the labelling for any approved product; the scope, progress and expansion of developing and commercializing UroGens product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis--vis alternative therapies. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGens Form 10-Q filed with the SEC on May 10, 2022 and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGens actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
Link:
- Understanding Menopause and its Symptoms | Menopause Treatment Options - Medriva - December 28th, 2023 [December 28th, 2023]
- Breast cancer survivor Jayne Pritchard talks alternative therapies over tea - MidlandToday - December 28th, 2023 [December 28th, 2023]
- 12 unusual ways Israelis are volunteering during the war - ISRAEL21c - December 28th, 2023 [December 28th, 2023]
- Complementary and alternative medicine - NHS - December 26th, 2022 [December 26th, 2022]
- Alternative Treatment (CAM) for MS: Types, Side Effects & Cost - December 26th, 2022 [December 26th, 2022]
- Complementary and alternative medicine | History & Facts - December 26th, 2022 [December 26th, 2022]
- Alternative medicine: Definition, examples, benefits, and risks - October 28th, 2022 [October 28th, 2022]
- Alternative Medicine: The Science Behind 10 Alternative Therapies - October 21st, 2022 [October 21st, 2022]
- Detoxification (alternative medicine) - Wikipedia - October 21st, 2022 [October 21st, 2022]
- Alternative Approaches to Mental Health and Wellbeing - Psychiatric Times - October 19th, 2022 [October 19th, 2022]
- New practice focuses on dental sleep medicine, providing an alternative for patients who use CPAP machines - PennLive - October 19th, 2022 [October 19th, 2022]
- Dr. Deepak Chopra Aligns with Plant-Based Therapeutics Company ProVEDA to Highlight Topical Pain Relief Solutions - Yahoo Finance - October 19th, 2022 [October 19th, 2022]
- True REST Float Spa Offers Free Floatation Therapy Session to Veterans - AccessWire - October 19th, 2022 [October 19th, 2022]
- Youve been told you need surgery for degenerative disc disease and stenosis of the spine. Now what? - Sonoran News - October 19th, 2022 [October 19th, 2022]
- Can you take Paxlovid and heart disease medications at the same time? - Medical News Today - October 15th, 2022 [October 15th, 2022]
- Kardashian fans think theyve unlocked Kourtneys secret to hiding her pregnancy after spotting key detai... - The US Sun - October 15th, 2022 [October 15th, 2022]
- Cabinet approves B5bn for 'Andaman International Health Center' - The Phuket News - October 15th, 2022 [October 15th, 2022]
- Eye health and dynamics of the modern world - The Citizen - October 15th, 2022 [October 15th, 2022]
- The Holistic Review on Occurrence, Biology, Diagnosis, and Treatment of Oral Squamous Cell Carcinoma - Cureus - October 15th, 2022 [October 15th, 2022]
- 10 Deeper Causes of Tinnitus, and How to Treat It - The Epoch Times - October 15th, 2022 [October 15th, 2022]
- Complementary and Alternative Medicine (CAM) - GoodTherapy - October 13th, 2022 [October 13th, 2022]
- India's alternative medicine industry grows, boosted by COVID-19 pandemic - CNA - October 13th, 2022 [October 13th, 2022]
- QC Kinetix (Charlotte) Offers Alternative Treatments for Knee Pain and Sports Injuries - Yahoo Finance - October 13th, 2022 [October 13th, 2022]
- Plant Extracts Market is expected to generate a revenue of USD 85.09 Billion by 2030, Globally, at 6.33% CAGR: Verified Market Research - Yahoo... - October 13th, 2022 [October 13th, 2022]
- Neuroplasticity Nonsense Is Full of Red Flags - Science Based Medicine - October 13th, 2022 [October 13th, 2022]
- Diabetics won't be made to pay for alternative medicines, Pharmac says - Stuff - October 13th, 2022 [October 13th, 2022]
- Lili Reinhart Becomes A Reiki Master: My Journey Into Reiki Healing Cant Be Simplified - IMDb - October 13th, 2022 [October 13th, 2022]
- The DRIPBaR is Coming to Clarksville, TN on Oct 16, 2022 - PR Web - October 13th, 2022 [October 13th, 2022]
- How Dr. Oz Boosted an Osteopath Who Became a Top Spreader of Covid Misinformation Mother Jones - Mother Jones - October 13th, 2022 [October 13th, 2022]
- World Arthritis Day: Arthritis and Women - Times of India - October 13th, 2022 [October 13th, 2022]
- What Is Alternative Medicine? - American Cancer Society - October 6th, 2022 [October 6th, 2022]
- Herbal medicine: Types, uses, and safety - Medical News Today - October 6th, 2022 [October 6th, 2022]
- WCI Health LLC, Your Alternative Health and Wellness Hub Will Be a Vendor and Presenter at Wonderland Miami by Microdose - StreetInsider.com - October 6th, 2022 [October 6th, 2022]
- The Viral Real - Journal #130 October 2022 - E-Flux - October 6th, 2022 [October 6th, 2022]
- Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo... - October 6th, 2022 [October 6th, 2022]
- Woman, 37, dies after herbal supplements led to liver failure: coroner - Insider - October 6th, 2022 [October 6th, 2022]
- What Is Vitiligo? All About This Unique Skin Condition That Impacts Skin Pigmentation, and How To Treat It - Parade Magazine - October 6th, 2022 [October 6th, 2022]
- Herbalist's Resource Guide to Cannabis and Other Plants That Can Prevent Cancer - PR Web - October 6th, 2022 [October 6th, 2022]
- Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Bas - Benzinga - October 6th, 2022 [October 6th, 2022]
- "Sh*t, I just want to get better. Thats what pushed me to do it, and it worked well" Chauncey Billups and other NBA stars on acupuncture -... - October 6th, 2022 [October 6th, 2022]
- People Science and Symbiome Partner to study the microbiome in the real world - Benzinga - October 6th, 2022 [October 6th, 2022]
- Bob Newhart Proves 93 Is the New 39 - Eat This, Not That - September 29th, 2022 [September 29th, 2022]
- Medical cannabis could be better alternative to opioids in managing pain - The Tribune India - September 29th, 2022 [September 29th, 2022]
- Woman killed by herbal remedies she took to treat arthritis - Evening Standard - September 29th, 2022 [September 29th, 2022]
- Get To Know The Best Natural Adderall Alternatives - Over The Counter and Non Prescription - Outlook India - September 29th, 2022 [September 29th, 2022]
- King Charles III Has a History of Promoting 'Quackery' Alternative Medicine - Newsweek - September 9th, 2022 [September 9th, 2022]
- Remedy Place: The Fashionable Social Wellness Club Where You Can Bring All Your Friends - Vogue - September 9th, 2022 [September 9th, 2022]
- Thailand heightens its healthcare hub ambition with integrative medicine - PR Newswire UK - September 9th, 2022 [September 9th, 2022]
- How bogus cancer treatments prey on the most vulnerable - Coda Story - September 9th, 2022 [September 9th, 2022]
- Management of Chronic Migraine in Children and Adolescents | PHMT - Dove Medical Press - September 9th, 2022 [September 9th, 2022]
- Mouth Taping: Is It Safe? - Health Essentials - September 9th, 2022 [September 9th, 2022]
- Queen Elizabeth: Seven things you need to know about the Queens passing - Toronto Star - September 9th, 2022 [September 9th, 2022]
- Building an Alternative Medical Economy in Response to 'Tyranny': Telehealth CEO - The Epoch Times - August 30th, 2022 [August 30th, 2022]
- Sesame oil: Nutrition, benefits, and more - Medical News Today - August 30th, 2022 [August 30th, 2022]
- Regenerative Medicine: An alternative to surgery and pills | Loop Cayman Islands - Loop News Cayman - August 30th, 2022 [August 30th, 2022]
- Find Euphoria: the luxury Greek spa retreat to visit now - Tatler - August 30th, 2022 [August 30th, 2022]
- What Is Synthetic Urine & How Does It Help To Pass A Drug Test? - The Island Now - August 30th, 2022 [August 30th, 2022]
- The science behind the healthtech startup must be understood well - Express Healthcare - August 30th, 2022 [August 30th, 2022]
- Best-in-class second-line HIV treatment rolls out in Zambia and Nigeria - Clinton Health Access Initiative - August 30th, 2022 [August 30th, 2022]
- Therapeutic effect of HFNC and NIV in patients with AECOPD | COPD - Dove Medical Press - August 30th, 2022 [August 30th, 2022]
- Five years after Kymriah: Ensuring the next cell and gene therapies reach patients - STAT - August 30th, 2022 [August 30th, 2022]
- Meet these renowned healthcare professionals who assist us in leading healthier lives - Oneindia - August 30th, 2022 [August 30th, 2022]
- Diet and Vitiligo: The Story So Far - Cureus - August 29th, 2022 [August 29th, 2022]
- Fatphobia Sucks, Especially If You're Trying to Have a Baby - VICE - August 29th, 2022 [August 29th, 2022]
- Orthomolecular Medicine, A Predictive Tool - Nation World News - August 29th, 2022 [August 29th, 2022]
- COVID-19 vaccines and the Nuremberg Code - Science Based Medicine - August 29th, 2022 [August 29th, 2022]
- Bolstering the Blood-CNS Barrier Could Lead to New Treatment Approach for Multiple Sclerosis - University of Utah Health Care - August 29th, 2022 [August 29th, 2022]
- Lockdowns Postponed the Inevitable. Is That a Bad Thing? - Science Based Medicine - August 29th, 2022 [August 29th, 2022]
- The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review - Cureus - August 27th, 2022 [August 27th, 2022]
- Ayurveda As Alternative Medicine: Research And Development To Be Taken Ahead By Heal In India - Entrepreneur - August 27th, 2022 [August 27th, 2022]
- French Doctolib platform accused of 'promoting alternative medicine' - The Connexion - August 27th, 2022 [August 27th, 2022]
- Chronic Fatigue Syndrome: Best Ways for Treating This Condition - Healthline - August 27th, 2022 [August 27th, 2022]
- Ellen White reveals "traumatic" incident that played huge role in her retirement - GIVEMESPORT - August 27th, 2022 [August 27th, 2022]
- Curcumin and Non-Hodgkin's Lymphoma: Does It Help? - Healthline - August 27th, 2022 [August 27th, 2022]
- In Denial: When Patients Don't Want to Believe They Have Cancer - Medscape - August 27th, 2022 [August 27th, 2022]
- Piotr Szyhalski depicts living through COVID-19 and other extreme historical phenomena - MinnPost - August 27th, 2022 [August 27th, 2022]
- Researchers identify chemo alternative for targeted treatment of leukemia patients - Devdiscourse - August 27th, 2022 [August 27th, 2022]
- India Can Show The World The Right Path For Medical Pluralism - News18 - August 27th, 2022 [August 27th, 2022]
- Complementary and Integrative Medicine - Reeve Foundation - Christopher Reeve Foundation - August 23rd, 2022 [August 23rd, 2022]
- Back pain: Exploring alternative treatments - Health - Life & Style - Ahram Online - August 23rd, 2022 [August 23rd, 2022]